BiotechTube

PIPE-791 Dose A + PIPE-791 Dose B + Placebo

Phase 2Recruiting
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Idiopathic Pulmonary Fibrosis

Conditions

Idiopathic Pulmonary Fibrosis

Trial Timeline

Jan 8, 2026 → Jun 1, 2028

NCT ID
NCT07284459

About PIPE-791 Dose A + PIPE-791 Dose B + Placebo

PIPE-791 Dose A + PIPE-791 Dose B + Placebo is a phase 2 stage product being developed by Contineum Therapeutics for Idiopathic Pulmonary Fibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07284459. Target conditions include Idiopathic Pulmonary Fibrosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07284459Phase 2Recruiting

Competing Products

20 competing products in Idiopathic Pulmonary Fibrosis

See all competitors
ProductCompanyStageHype Score
KPL-716 + PlaceboKiniksa PharmaceuticalsPhase 2
47
Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 1
25
LTI-03 + PlaceboRein TherapeuticsPhase 2
44
Tirzepatide + Tirzepatide PlaceboEli LillyApproved
85
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
77
Zimura + EyleaAstellas PharmaPhase 2
52
Avacincaptad PegolAstellas PharmaPhase 2
52
Rituximab + cyclosporineSun PharmaceuticalPhase 3
77
E5501EisaiPhase 1
33
E5501 + Drug: E5501EisaiPhase 1
33
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
33
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
77
Placebo + Avatrombopag tabletsEisaiPhase 2
52
PerampanelEisaiPre-clinical
23
Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets)EisaiPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77

Other Products from Contineum Therapeutics

PIPE-307 Dose A + PIPE-307 Dose B + PlaceboPhase 2
44
PIPE-505 + PlaceboPhase 1/2
33
PIPE-307Phase 1
25
PIPE-791 + PlaceboPhase 1
25
PIPE-307 + Placebo oral tabletPhase 1
25